Elon Musk announced that Neuralink plans to begin high-volume production of brain-computer interface devices by 2026. The company aims to implement a nearly fully automated surgical procedure, which will allow device threads to pass through the dura mater without needing to remove it. This advancement is significant as it could enhance the safety and efficiency of the surgical process. In a related note, S.E. Robinson Jr. shared that Neuralink received FDA Breakthrough Device Designation in 2025 for its speech restoration technology, targeting severe speech impairments. The company also launched its first clinical trial in the Middle East at the Cleveland Clinic Abu Dhabi, indicating its expanding global reach and commitment to addressing complex health challenges. The announcement has drawn considerable attention, with Musk's tweet garnering 12 million views. This level of engagement highlights the public's interest in Neuralink's developments and their potential impact on medical technology.